CareRx Management
Management criteria checks 2/4
CareRx's CEO is Puneet Khanna, appointed in May 2023, has a tenure of 3.08 years. total yearly compensation is CA$1.38M, comprised of 32.4% salary and 67.6% bonuses, including company stock and options. directly owns 0.38% of the company’s shares, worth CA$755.10K. The average tenure of the management team and the board of directors is 1.5 years and 4.2 years respectively.
Key information
Puneet Khanna
Chief executive officer
CA$1.4m
Total compensation
| CEO salary percentage | 32.41% |
| CEO tenure | 3.1yrs |
| CEO ownership | 0.4% |
| Management average tenure | 1.5yrs |
| Board average tenure | 4.2yrs |
Recent management updates
Recent updates
Narrative Update • Jun 01
CRRX: Share Repurchases And Higher Future P/E Will Support Upside Potential
Narrative Update on CareRx The average analyst price target for CareRx has shifted from CA$5.38 to CA$5.14. Analysts point to updated fair value estimates, a slightly higher discount rate, more cautious revenue growth assumptions, lower projected profit margins, and a higher future P/E multiple as key drivers of the change.
Narrative Update • May 04
CRRX: Completed Buyback And Stable Assumptions Will Support Long Term Upside
Analysts have nudged their CareRx price target slightly higher to CA$4.50, reflecting modest adjustments to the discount rate, revenue growth assumptions, profit margin outlook and future P/E expectations. What's in the News CareRx completed a share repurchase of 246,069 shares between October 1, 2025 and March 4, 2026, equal to 0.39% of its shares, for a total of CA$0.49 million (Key Developments).Narrative Update • Apr 19
CRRX: Share Repurchase And Steady Assumptions Will Support Long Term Upside
Analysts have made slight adjustments to their CareRx price targets, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. Their fair value estimate remains steady at CA$4.50.Narrative Update • Apr 05
CRRX: Share Repurchase And Margin Outlook Will Support Long Term Upside
Analysts have modestly revised their CareRx price target to CA$4.50, reflecting updated assumptions for discount rate, revenue growth, profit margins and future P/E, which keep the fair value estimate steady at CA$4.50. What's in the News CareRx completed a share repurchase of 246,069 shares, representing 0.39% of its shares, for a total of CA$0.49 million under the buyback announced on September 15, 2025 (Key Developments).Narrative Update • Mar 22
CRRX: Share Repurchases And Higher Assumed P/E Will Support Future Upside
Analysts have adjusted their CA$ fair value estimate for CareRx from about CA$5.08 to roughly CA$5.38, reflecting updated views on revenue growth, profit margins, and future P/E assumptions. What's in the News CareRx completed a share repurchase program, buying back 246,069 shares between October 1, 2025 and March 4, 2026, equal to 0.39% of its shares, for a total of CA$0.49 million (Key Developments).Narrative Update • Mar 07
CRRX: Improved Profit Outlook And Lower P/E Will Support Future Upside
Analysts have adjusted their CareRx price target slightly higher to CA$5.08 from CA$4.92, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Valuation Changes Fair Value: CA$5.08, up slightly from CA$4.92.Narrative Update • Feb 21
CRRX: Lower Future P/E Will Support Stronger Shareholder Returns
Analysts have trimmed their target price on CareRx to CA$4.92. They link this move to slightly higher discount rate assumptions and a modestly lower revenue growth outlook, partially balanced by a small improvement in expected profit margins and a lower future P/E estimate.Narrative Update • Feb 06
CRRX: Refined Earnings Assumptions Will Support Stronger Long Term Upside Potential
Analysts have slightly adjusted their price target on CareRx, citing updated assumptions around revenue growth, profit margins, discount rate and future P/E that fine tune rather than overhaul their previous fair value view. Valuation Changes Fair Value: Unchanged at 4.5x, indicating no shift in the overall valuation anchor used in the model.Narrative Update • Jan 23
CRRX: Future Earnings Power Will Support Refined Fair Value Upside
Analysts have slightly adjusted their price target on CareRx, reflecting modest tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions. Together these changes point to a more refined view of the company’s fair value around $4.50.Narrative Update • Jan 09
CRRX: Future Earnings Power Will Drive Repriced Market Expectation
The analyst price target for CareRx has shifted from US$2.25 to US$4.50, with analysts attributing this change to updated assumptions about revenue growth, profitability, and future P/E. What's in the News Between September 15, 2025 and September 30, 2025, CareRx reported no share repurchases under its existing buyback program, with 0 shares repurchased for CAD 0 million in that period (Key Developments).Narrative Update • Dec 24
CRRX: Higher Future Earnings Multiple Will Drive Stronger Shareholder Returns
Analysts have nudged their price target for CareRx slightly higher, raising it by about $0.06 per share. This reflects modestly stronger expectations for revenue growth and valuation multiples, despite a more cautious view on profit margins.Narrative Update • Dec 10
CRRX: Upcoming Share Buybacks Will Support Stronger Future Shareholder Returns
Narrative Update on CareRx Analysts have modestly increased their price target on CareRx to reflect a slightly higher valuation multiple and stable expectations for revenue growth and profit margins. This translates into a small upward adjustment in projected equity value by a few cents per share.Narrative Update • Nov 26
CRRX: Share Repurchase Program Will Drive Stronger Performance Ahead
Analysts have raised their price target for CareRx, increasing the fair value estimate from $4.00 to $4.86. This change reflects improved revenue growth expectations and a more favorable profit margin outlook.Analysis Article • Sep 11
Is CareRx (TSE:CRRX) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
New Narrative • Apr 07
North Burnaby Fulfillment Center And European Automation Will Improve Operations
Debt restructuring and cost-saving measures likely increase net margins and improve earnings by reducing interest expenses and operational costs.Analysis Article • Feb 11
Market Participants Recognise CareRx Corporation's (TSE:CRRX) Revenues
It's not a stretch to say that CareRx Corporation's ( TSE:CRRX ) price-to-sales (or "P/S") ratio of 0.4x right now...Analysis Article • Oct 03
CareRx (TSE:CRRX) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Aug 11
Analyst Estimates: Here's What Brokers Think Of CareRx Corporation (TSE:CRRX) After Its Second-Quarter Report
Last week, you might have seen that CareRx Corporation ( TSE:CRRX ) released its quarterly result to the market. The...Analysis Article • Apr 22
Does CareRx (TSE:CRRX) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analysis Article • Mar 17
Market Participants Recognise CareRx Corporation's (TSE:CRRX) Revenues Pushing Shares 28% Higher
CareRx Corporation ( TSE:CRRX ) shares have continued their recent momentum with a 28% gain in the last month alone...Analysis Article • Oct 19
CareRx (TSE:CRRX) Takes On Some Risk With Its Use Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Analysis Article • Aug 22
What You Can Learn From CareRx Corporation's (TSE:CRRX) P/S
It's not a stretch to say that CareRx Corporation's ( TSE:CRRX ) price-to-sales (or "P/S") ratio of 0.3x right now...Analysis Article • Sep 22
CareRx (TSE:CRRX) Has A Somewhat Strained Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | CA$27m |
| Dec 31 2025 | CA$1m | CA$447k | CA$26m |
| Sep 30 2025 | n/a | n/a | CA$93k |
| Jun 30 2025 | n/a | n/a | -CA$2m |
| Mar 31 2025 | n/a | n/a | -CA$4m |
| Dec 31 2024 | CA$1m | CA$436k | -CA$5m |
| Sep 30 2024 | n/a | n/a | -CA$6m |
| Jun 30 2024 | n/a | n/a | -CA$7m |
| Mar 31 2024 | n/a | n/a | -CA$4m |
| Dec 31 2023 | CA$1m | CA$371k | -CA$5m |
| Sep 30 2023 | n/a | n/a | -CA$6m |
| Jun 30 2023 | n/a | n/a | -CA$7m |
| Mar 31 2023 | n/a | n/a | -CA$34m |
| Dec 31 2022 | CA$733k | CA$261k | -CA$34m |
| Sep 30 2022 | n/a | n/a | -CA$34m |
| Jun 30 2022 | n/a | n/a | -CA$36m |
| Mar 31 2022 | n/a | n/a | -CA$20m |
| Dec 31 2021 | CA$500k | CA$250k | -CA$23m |
| Sep 30 2021 | n/a | n/a | -CA$21m |
| Jun 30 2021 | n/a | n/a | -CA$24m |
| Mar 31 2021 | n/a | n/a | -CA$29m |
| Dec 31 2020 | CA$346k | CA$42k | -CA$18m |
Compensation vs Market: Puneet's total compensation ($USD985.56K) is above average for companies of similar size in the Canadian market ($USD154.42K).
Compensation vs Earnings: Puneet's compensation has been consistent with company performance over the past year.
CEO
Puneet Khanna
3.1yrs
Tenure
CA$1,378,132
Compensation
Mr. Puneet Khanna has been Chief Executive Officer and President at CareRx Corporation since May 31, 2023 and as its Director since June 06, 2023. He was the Chief Operating Officer at CareRx Corporation f...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 3.1yrs | CA$1.38m | 0.38% CA$ 755.1k | |
| Chief Financial Officer | 1.7yrs | CA$668.15k | no data | |
| Chief Operating Officer | 1yr | CA$479.99k | 0.074% CA$ 148.7k | |
| Chief Employee & Customer Experience Officer | 1.2yrs | CA$545.06k | 0.12% CA$ 230.3k | |
| Chief Clinical Officer | 2.4yrs | CA$485.45k | 0.25% CA$ 493.9k | |
| Senior Vice President of Information Technology | 1.3yrs | no data | no data | |
| Vice President of Business Planning & Analysis | no data | no data | no data |
1.5yrs
Average Tenure
Experienced Management: CRRX's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 3yrs | CA$1.38m | 0.38% CA$ 755.1k | |
| Director | 1yr | CA$77.69k | 0.0020% CA$ 4.0k | |
| Independent Director | 4.2yrs | CA$123.49k | 0.077% CA$ 154.4k | |
| Independent Director | 9.3yrs | CA$115.03k | 0.067% CA$ 134.5k | |
| Independent Chairman | 3yrs | CA$212.31k | 0.12% CA$ 246.7k | |
| Director | 6.6yrs | CA$102.35k | 0.23% CA$ 453.2k | |
| Independent Director | 6.1yrs | CA$102.35k | 0.12% CA$ 242.7k |
4.2yrs
Average Tenure
Experienced Board: CRRX's board of directors are considered experienced (4.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/16 23:08 |
| End of Day Share Price | 2026/06/16 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CareRx Corporation is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kyle McPhee | ATB Cormark |
| Kyle McPhee | ATB Cormark Historical (Cormark Securities) |
| Doug Cooper | Beacon Securities Limited |